National Institutes of Health logo
Program

Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge – Phase I

Paid up to $20,000 each to as many as 25 winners in Phase I of a three-phase NIH challenge for technologies that target RNA directly to treat human disease.

National Institutes of HealthUnited StatesPrize
About

This is Phase I of the NIH's three-phase TRDNT Challenge, run through the NIH Common Fund Venture Program. Participants proposed a novel RNA-targeting technology and explained how it could become a prototype; Phase I is now closed, with up to 25 winners sharing a $500,000 purse and results due to be announced in September 2026. The wider challenge continues into a Phase II prototype-development st…

Industries covered
BiotechMedtech
Grants under Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge – Phase I

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.

Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge – Phase I
Between cycles

Paid up to $20,000 each to as many as 25 winners in Phase I of a three-phase NIH challenge for technologies that target RNA directly to treat human disease.

$500K pool